NASDAQ:CRVS Corvus Pharmaceuticals - CRVS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.84 +0.02 (+2.44%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.81▼$0.8850-Day Range$0.77▼$1.0452-Week Range$0.70▼$2.17Volume69,113 shsAverage Volume113,801 shsMarket Capitalization$39.13 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Corvus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside375.9% Upside$4.00 Price TargetShort InterestHealthy0.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 2 Articles This WeekInsider TradingAcquiring Shares$75,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.70 out of 5 starsMedical Sector81st out of 1,030 stocksPharmaceutical Preparations Industry27th out of 502 stocks 3.5 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Corvus Pharmaceuticals has a forecasted upside of 375.9% from its current price of $0.84.Amount of Analyst CoverageCorvus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.49% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 3.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 3.1 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Corvus Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest9 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $75,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders29.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.45% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.92) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corvus Pharmaceuticals (NASDAQ:CRVS) StockCorvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.Read More Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesFebruary 2, 2023 | finance.yahoo.comQuite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholdersJanuary 30, 2023 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated by Analysts at StockNews.comFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 20, 2023 | forbes.comCorvus PharmaceuticalsJanuary 13, 2023 | reuters.comCRVS.A - | Stock Price & Latest News | ReutersDecember 12, 2022 | finance.yahoo.comCorvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 5, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022November 14, 2022 | finance.yahoo.comJames Rosenbaum Presented the Distinguished Service Award by the American College of RheumatologyFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 4, 2022 | apnews.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionNovember 2, 2022 | msn.comEarnings Preview For Corvus PharmaceuticalsOctober 27, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022October 25, 2022 | finance.yahoo.comCorvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell CancerSeptember 27, 2022 | finance.yahoo.comCorvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck CancerSeptember 26, 2022 | finance.yahoo.comCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in ChinaSeptember 15, 2022 | nasdaq.comA number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholdersSeptember 6, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 26, 2022 | finance.yahoo.comGreat news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last yearAugust 11, 2022 | finance.yahoo.comCorvus (CRVS) Moves to Buy: Rationale Behind the UpgradeAugust 8, 2022 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 28, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022July 21, 2022 | finance.yahoo.comCorvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of ResearchMay 10, 2022 | finance.yahoo.comCorvus Pharmaceuticals Provides Program Updates at R&D SymposiumSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Company Calendar Last Earnings10/31/2021Today2/02/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+375.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.08% Return on Assets-42.46% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book0.40Miscellaneous Outstanding Shares46,550,000Free Float32,727,000Market Cap$39.13 million OptionableNot Optionable Beta1.02 Key ExecutivesRichard A. MillerChairman, President & Chief Executive OfficerLeiv LeaChief Financial OfficerGabriel LucianoVice President-Clinical OperationsSuresh MahabhashyamVice President-Clinical DevelopmentJames RosenbaumSenior Vice President-ResearchKey CompetitorsBioLineRxNASDAQ:BLRXCumberland PharmaceuticalsNASDAQ:CPIXAkari TherapeuticsNASDAQ:AKTXFSD PharmaNASDAQ:HUGEAvalo TherapeuticsNASDAQ:AVTXView All CompetitorsInsiders & InstitutionsWilliam Benton JonesBought 20,000 shares on 12/20/2022Total: $15,800.00 ($0.79/share)Richard A Md MillerBought 50,000 shares on 12/13/2022Total: $37,000.00 ($0.74/share)Leiv LeaBought 30,000 shares on 12/13/2022Total: $22,200.00 ($0.74/share)Telemetry Investments L.L.C.Bought 61,906 shares on 11/17/2022Ownership: 1.121%Two Sigma Advisers LPBought 106,700 shares on 11/15/2022Ownership: 1.031%View All Insider TransactionsView All Institutional Transactions CRVS Stock - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price forecast for 2023? 3 brokerages have issued twelve-month price objectives for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $2.00 to $6.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 375.9% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2023? Corvus Pharmaceuticals' stock was trading at $0.85 at the start of the year. Since then, CRVS stock has decreased by 1.1% and is now trading at $0.8405. View the best growth stocks for 2023 here. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our CRVS earnings forecast. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings data on Sunday, October, 31st. The company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? (CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. What is Corvus Pharmaceuticals' stock symbol? Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS." Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corvus Pharmaceuticals' stock price today? One share of CRVS stock can currently be purchased for approximately $0.84. How much money does Corvus Pharmaceuticals make? Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $39.13 million. The company earns $-43,240,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How can I contact Corvus Pharmaceuticals? Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com. This page (NASDAQ:CRVS) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.